Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Luis Lara-Mejia"'
Autor:
Diego de Miguel‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen, Christian Rolfo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-6 (2024)
Abstract Background Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable pr
Externí odkaz:
https://doaj.org/article/aef1eb16e7a04127b7be386a1b11b7d4
Autor:
Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia, Andres F. Cardona, Aung Naing, Sunjay Kaushal, Fred R. Hirsch, Philip C. Mack, Maria Jose Serrano, Vincenzo Adamo, Rivka R. Colen, Christian Rolfo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid
Externí odkaz:
https://doaj.org/article/4c65ef22566e4f538c868b2b0b00c400
Autor:
David, Heredia, Feliciano, Barrón, Andrés F, Cardona, Saul, Campos, Jerónimo, Rodriguez-Cid, Luis, Martinez-Barrera, Jorge, Alatorre, Miguel Ángel, Salinas, Luis, Lara-Mejia, Diana, Flores-Estrada, Oscar, Arrieta
Publikováno v:
Future oncology (London, England). 17(2)
Autor:
Oscar Arrieta, Laura Margarita Bolaño-Guerra, Enrique Caballé-Pérez, Luis Lara-Mejía, Jenny G. Turcott, Salvador Gutiérrez, Francisco Lozano-Ruiz, Luis Cabrera-Miranda, Andrés Mauricio Arroyave-Ramírez, Federico Maldonado-Magos, Luis Corrales, Claudio Martín, Ana Pamela Gómez-García, Bernardo Cacho-Díaz, Andrés F. Cardona
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDifferent prognostic scales exist in patients with brain metastasis, particularly in lung cancer. The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA index) for brain metastases is a powerful prognostic too
Externí odkaz:
https://doaj.org/article/014ecf5839d84666b3f0118f41988555
Autor:
Alejandro Avilés-Salas, Diego A. Díaz-García, Luis Lara-Mejía, Andrés F. Cardona, Mario Orozco-Morales, Rodrigo Catalán, Norma Y. Hernández-Pedro, Eduardo Rios-Garcia, Maritza Ramos-Ramírez, Oscar Arrieta
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 333-343 (2022)
(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistr
Externí odkaz:
https://doaj.org/article/6d051a4228fc434cb2e0e286fad4a2e5
Autor:
Alejandro Avilés‐Salas, Diana Flores‐Estrada, Luis Lara‐Mejía, Rodrigo Catalán, Graciela Cruz‐Rico, Mario Orozco‐Morales, David Heredia, Laura Bolaño‐Guerra, Pamela Denisse Soberanis‐Piña, Edgar Varela‐Santoyo, Andrés F. Cardona, Oscar Arrieta
Publikováno v:
Thoracic Cancer, Vol 13, Iss 23, Pp 3362-3373 (2022)
Abstract Background Programmed death ligand‐1 (PD‐L1) expression predicts immunotherapy utility in nononcogenic addictive lung adenocarcinoma (ADC). However, its reproducibility and reliability may be compromised outside clinical trials. This stu
Externí odkaz:
https://doaj.org/article/ab7624f0becc45a988ce49574b7ebcc8
Autor:
Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Lung cancer (LC) is one of the most common causes of death worldwide. The identification of oncogene-addicted driving mutations suitable for targeted therapy has improved clinical outcomes in advanced diseases. Clinical trials, on the other hand, rar
Externí odkaz:
https://doaj.org/article/97f458914fea497dbd8b05ee52644cbf
Autor:
Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Alejandro Avilés-Salas, Rodrigo Catalán, Luis Lara-Mejía, Suraj Samtani-Bassarmal, Andres F. Cardona, Jorge Mendoza-Desión, Daniel Hernández-Cueto, Altagracia Maldonado, Guillermina Baay-Guzmán, Sara Huerta-Yepes, Oscar Arrieta
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Malignant Pleural Mesothelioma (MPM) is a rare but aggressive neoplasia that usually presents at advanced stages. Even though some advances have been achieved in the management of patients with MPM, this malignancy continuous to i
Externí odkaz:
https://doaj.org/article/4bb5fae34e0d4cf4a0b815d426954ba7
Autor:
Oscar Arrieta, Rodrigo Catalán, Silvia Guzmán-Vazquez, Feliciano Barrón, Luis Lara-Mejía, Herman Soto-Molina, Maritza Ramos-Ramírez, Diana Flores-Estrada, Jaime de la Garza
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations. The counterpart of these drugs is the financial burden that they impose, whi
Externí odkaz:
https://doaj.org/article/a271e89161d143bbbc8a2934bd76b46f
Autor:
Alessandro Russo, Christian Rolfo, Andrés Cardona, Aung Naing, Rivka Colen, Christine Peterson, Diego de Miguel Perez, Muthukumar Gunasekaran, Vincenzo Adamo, Oscar Arrieta, Feliciano Barrón, Luis Lara-Mejía, Philip Mack, Fred Hirsch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/56b5b8b57e944be291f269ed6586c2b9